22 October 2016
Meeting category
Date(s)
22 Oct 2016
Location
Glasgow,
United Kingdom
Organizer
European HIV Clinical Forum 2016
Related Enduring Materials
Enduring Materials
Next Generation of Antiretroviral Drugs: Oral Versus Injectable Delivery -
Chairs
Impact on: Virology/Resistance
Impact on: Pharmacology – penetration to sanctuary sites and drug-drug interactions
Abstracts Presentation -
Chairs
A Multicenter Observational Study on the Efficacy and Tolerability of Dolutegravir combined with Tenofovir/Emtricitabine or Abacavir/Lamivudine as a Switch Strategy for HIV-1 Positive, Antiretroviral-experienced Patients with Stable Viral Suppression
Efficacy of integrase strand transfer inhibitors in different HIV-1 subtypes
Kamlendra Singh
O_o2
Virological failure even at low levels of viremia can be associated to integrase strand-transfer inhibitors resistance in HIV-1 infected patients
An Italian case of transmitted integrase inhibitor resistance in a drug-naïve patient: a refined analysis by ultra-deep-454 pyrosequencing
French National survey of resistance to integrase inhibitors shows high differences of resistance selection rate in case of virological failure in a context of routine hospital care (ANRS AC11 virology network)
Tools to Improve the Clinician’s Management of Drug-Drug Interactions -
Anna Maria Geretti, MD, PhD, FRCPath
How to manage drug - drug interactions - the theory
Clinical Case Presentations – How to manage drug - drug interactions - the practice
University of Rome, Italy / King's College London, United Kingdom
Drugs to Address Challenging Populations -
Chairs
Clinical Utility of Integrase Inhibitors during pregnancy
Virological response of HIV-infected-patients virologically-suppressed switching to a DTG-based regimen in an observational cohort based on the genotypic susceptibility score
Lamivudine plus either Atazanavir/ritonavir, Darunavir/ritonavir or Dolutegravir as switch strategies in HIV-positive, virologically-suppressed patients: a comparison
Switching from combination antiretroviral therapy (cART) to dolutegravir (DTG) monotherapy in virologically suppressed HIV-1 infected adults: a randomized multicenter, non-inferiority clinical trial (DOMONO).
Antiretroviral Treatment Strategies -
Chairs
Deniz Gökengin, MD
Ege Üniversitesi, Turkey
Induction-Maintenance ARV Therapy: Why, Who, When and How?
Clinical Case Presentations - Experience with Induction-Maintenance Therapy in real life settings
Maintenance Therapy with Dolutegravir/Rilpivirin is efficient and well tolerated in a real-life setting
Overview
Welcome
The 2nd European HIV Clinical Forum was held on 22 October, 2016 in Glasgow (UK), preceding the HIV Glasgow meeting on Drug Therapy.
The meeting was an incredible success with nearly 100 attendees visiting the meeting!
The European HIV Clinical Forum focused entirely on Integrase Inhibitors as Integrase Inhibitors are rapidly gaining a central role in the routine care of HIV infected individuals. The HIV Clinical Forum meetings aim at enhancing the clinical skills and research capabilities of HIV healthcare professionals in regard to this unique class of antiretroviral drugs.
General Information
Meeting Objectives
With the HIV Clinical Forum program we aim to:
- Build a community of healthcare professionals devoted to providing optimal clinical care for their patients
- Create a platform for interactive information exchange on novel treatment options
- Translate the latest research achievements into clinical guidance for the optimal management of HIV-positive individuals
- Build a community of healthcare professionals devoted to providing optimal clinical care for their patients
- Create a platform for interactive information exchange on novel treatment options
- Translate the latest research achievements into clinical guidance for the optimal management of HIV-positive individuals
Learning Objectives
After participating in the HIV Clinical Forum, participants will be able to:
- Understand the clinical data supporting novel treatment strategies
- Describe the pros and cons of novel treatment strategies
- Understand how to integrate novel treatment strategies into routine patient care
- Be knowledgeable of the clinical data supporting long-acting injectable regimens
- Identify patients who might best benefit from long acting injectable regimens
- Know how best to integrate injectable drugs in to routine clinical care
- Understand the clinical data supporting novel treatment strategies
- Describe the pros and cons of novel treatment strategies
- Understand how to integrate novel treatment strategies into routine patient care
- Be knowledgeable of the clinical data supporting long-acting injectable regimens
- Identify patients who might best benefit from long acting injectable regimens
- Know how best to integrate injectable drugs in to routine clinical care
Language
